 Shares of Novavax NASDAQ: NVAX are in focus, as the biotechnology company will share data from its Covid-19-Influenza Combination CIC vaccine candidate for Phase 1 and 2 trials at the World Vaccine Congress WVC Europe 2022 event tomorrow. Novavax will also share data on its Covid-19 vaccine as a homologous and heterologous booster for adults over 18 and adolescents between 12 and 17. 